Literature DB >> 8255971

Adult-type Gaucher disease in children: genetics, clinical features and enzyme replacement therapy.

S Zevin1, A Abrahamov, I Hadas-Halpern, R Kannai, E Levy-Lahad, M Horowitz, A Zimran.   

Abstract

Clinical manifestations of type 1 (Adult) Gaucher disease usually start in childhood. However, most of the previously published data describe the features of this disorder in adults. We present the clinical and genetic characteristics of 34 children and adolescents with type 1 Gaucher disease evaluated in our clinic during the past two years. Patients were aged 2-18 years; 18 were boys and 16 girls. The majority presented before the age of 10. Growth retardation appeared as a prominent feature, with 26% in or below the third percentile in weight, and 30% so in height, especially in the youngest age group (2-5 years). Anaemia and thrombocytopenia occurred in 80% and 60% of the children, respectively. Hepatosplenomegaly was noted in all the children; only 3 were splenectomized. Skeletal involvement was evident on X-rays in 90% of the patients, but only 50% complained of bone pains. Three patients had severe bone disease, with avascular necrosis of the hip joint. Mutation analysis at the DNA level revealed the 1226/1226 genotype in 12 (35%) patients and 1226/84GG in 13 (38%). Correlation was found between the genotypes and the severity of the disease, including growth retardation. A positive response was documented in all 9 patients who completed 12 months of the recently-introduced enzyme replacement therapy for Gaucher disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8255971

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  8 in total

1.  Characteristics of gene mutations among 32 unrelated Japanese Gaucher disease patients: absence of the common Jewish 84GG and 1226G mutations.

Authors:  H Ida; K Iwasawa; H Kawame; O M Rennert; K Maekawa; Y Eto
Journal:  Hum Genet       Date:  1995-06       Impact factor: 4.132

2.  A disease severity scoring system for children with type 1 Gaucher disease.

Authors:  Staci Kallish; Paige Kaplan
Journal:  Eur J Pediatr       Date:  2012-09-20       Impact factor: 3.183

3.  Severe skeletal complications in Japanese patients with type 1 Gaucher disease.

Authors:  H Ida; O M Rennert; S Kato; T Ueda; K Oishi; K Maekawa; Y Eto
Journal:  J Inherit Metab Dis       Date:  1999-02       Impact factor: 4.982

Review 4.  Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements.

Authors:  Gregory A Grabowski; Generoso Andria; Antonio Baldellou; Pauline E Campbell; Joel Charrow; Ian J Cohen; Chris M Harris; Paige Kaplan; Eugen Mengel; Miguel Pocovi; Ashok Vellodi
Journal:  Eur J Pediatr       Date:  2003-12-16       Impact factor: 3.183

5.  Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1.

Authors:  Gregory A Grabowski; Katherine Kacena; J Alexander Cole; Carla E M Hollak; Lin Zhang; John Yee; Pramod K Mistry; Ari Zimran; Joel Charrow; Stephan vom Dahl
Journal:  Genet Med       Date:  2009-02       Impact factor: 8.822

6.  Current and emerging pharmacotherapy for Gaucher disease in pediatric populations.

Authors:  Richard Sam; Emory Ryan; Emily Daykin; Ellen Sidransky
Journal:  Expert Opin Pharmacother       Date:  2021-03-25       Impact factor: 4.103

7.  Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review.

Authors:  Divair Doneda; Cristina B Netto; Cileide C Moulin; Ida Vanessa D Schwartz
Journal:  Nutr Metab (Lond)       Date:  2013-04-09       Impact factor: 4.169

Review 8.  Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease.

Authors:  Ari Zimran; Michael Wajnrajch; Betina Hernandez; Gregory M Pastores
Journal:  Orphanet J Rare Dis       Date:  2018-02-23       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.